Intended Use

Indicated for the analysis of REMI Remote EEG Monitoring System electroencephalogram (EEG) recordings to mark sections that may correspond to potential electrographic seizures lasting at least 10 seconds. Intended for use by physicians qualified in EEG analysis as an aid during EEG review for adult and pediatric patients (6+ years). Does not provide real-time marking or diagnostic conclusions.

Technology

Software as a medical device (SaMD) analyzes previously acquired 4-channel EEG data collected bilaterally from frontal and temporoparietal scalp regions via REMI sensors. It automatically identifies and annotates regions that may correspond to electrographic seizures lasting at least 10 seconds to assist physicians in EEG review.

Performance

The device underwent software verification, clinical validation, and human factors validation. Clinical validation showed a sensitivity of 86.2% for detecting electrographic seizures with a false alarm rate of 0.162 false positives per hour, demonstrating safety and effectiveness for its intended use.

Predicate Devices

No predicate devices specified

Device Timeline

  • 1

    Submission

    6/16/2023

    6 months
  • 2

    FDA Approval

    1/3/2024

Other devices from Epitel, Inc.

Ready to Sharpen Your Edge?

Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.